Turtle Creek Wealth Advisors LLC Buys 11,092 Shares of Astrazeneca Plc $AZN

Turtle Creek Wealth Advisors LLC grew its stake in shares of Astrazeneca Plc (NYSE:AZN) by 19.2% in the 4th quarter, Holdings Channel.com reports. The fund owned 68,841 shares of the company’s stock after acquiring an additional 11,092 shares during the period. Turtle Creek Wealth Advisors LLC’s holdings in Astrazeneca were worth $6,329,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Binnacle Investments Inc increased its holdings in shares of Astrazeneca by 21.8% during the third quarter. Binnacle Investments Inc now owns 660 shares of the company’s stock valued at $51,000 after acquiring an additional 118 shares in the last quarter. 44 Wealth Management LLC boosted its position in shares of Astrazeneca by 0.7% during the third quarter. 44 Wealth Management LLC now owns 16,722 shares of the company’s stock valued at $1,283,000 after buying an additional 124 shares during the last quarter. CoreCap Advisors LLC boosted its position in shares of Astrazeneca by 30.6% during the third quarter. CoreCap Advisors LLC now owns 534 shares of the company’s stock valued at $41,000 after buying an additional 125 shares during the last quarter. Traub Capital Management LLC raised its position in Astrazeneca by 3.3% in the 3rd quarter. Traub Capital Management LLC now owns 4,115 shares of the company’s stock worth $316,000 after buying an additional 130 shares during the last quarter. Finally, PFG Investments LLC raised its position in Astrazeneca by 2.7% in the 3rd quarter. PFG Investments LLC now owns 5,306 shares of the company’s stock worth $407,000 after buying an additional 137 shares during the last quarter. 20.35% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have issued reports on AZN. Citigroup began coverage on shares of Astrazeneca in a research note on Tuesday, January 27th. They set a “buy” rating on the stock. Barclays restated an “overweight” rating on shares of Astrazeneca in a research note on Tuesday, January 6th. TD Cowen restated a “buy” rating on shares of Astrazeneca in a research note on Wednesday, March 18th. Weiss Ratings began coverage on shares of Astrazeneca in a research note on Wednesday, March 11th. They set a “buy (b)” rating on the stock. Finally, Morgan Stanley restated an “overweight” rating on shares of Astrazeneca in a research note on Wednesday, April 8th. Eight investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $102.67.

Astrazeneca Price Performance

Shares of AZN opened at $192.35 on Friday. The company has a market cap of $298.31 billion, a P/E ratio of 33.13, a price-to-earnings-growth ratio of 1.47 and a beta of 0.35. Astrazeneca Plc has a 12-month low of $132.32 and a 12-month high of $212.71. The company has a debt-to-equity ratio of 0.51, a quick ratio of 0.72 and a current ratio of 0.94.

Astrazeneca Announces Dividend

The company also recently disclosed a dividend, which was paid on Monday, March 23rd. Shareholders of record on Friday, February 20th were paid a $1.595 dividend. The ex-dividend date of this dividend was Friday, February 20th. This represents a yield of 156.0%. Astrazeneca’s payout ratio is presently 74.83%.

About Astrazeneca

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.